Efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA trial.
Antonio PérezFrancisco Javier Carrasco SánchezCarlos GonzálezJosé Miguel Seguí-RipollCarlos TrescolíJavier EnaMireia BorrellRicardo Gomez HuelgasPublished in: BMJ open diabetes research & care (2021)
Inpatient and intensification therapy at discharge with Gla-300 improved significantly glycemic control of patients with type 2 diabetes insufficiently controlled with other basal insulin and/or non-insulin antidiabetic medication, with high treatment satisfaction. Gla-300 could therefore be a treatment choice for hospital and postdischarge diabetes management.
Keyphrases
- glycemic control
- type diabetes
- blood glucose
- weight loss
- insulin resistance
- healthcare
- cardiovascular disease
- clinical trial
- stem cells
- mental health
- emergency department
- acute care
- combination therapy
- randomized controlled trial
- adverse drug
- metabolic syndrome
- study protocol
- adipose tissue
- cell therapy
- open label
- smoking cessation